Abstract
Effect of direct acting antiviral treatment (DAAs), as a new treatment of chronic viral hepatitis C on patients with heart failure
Highlights
Hepatitis C virus (HCV) infection is a persistent viral infection of the liver and considered as a considerable health dilemma globally especially in Egypt
Regarding Echocardiography data: There is no significant difference in Ejection fraction (EF) regarding studied groups before and after treatment (P= 0.06) table [1]
On studying the difference in EF regarding both studied group before and after finishing the course of antiviral treatment, there is no significant difference in EF between the studied regimens of treatment before and after finishing the course of antiviral treatment (P= 0.989) table [2]
Summary
Hepatitis C virus (HCV) infection is a persistent viral infection of the liver and considered as a considerable health dilemma globally especially in Egypt. Treatment for chronic hepatitis C virus infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents. Aim of the work: The aim of this study is to evaluate the effect of new antiviral treatments regarding heart failure in patients with chronic viral hepatitis “c”. Treatment for chronic hepatitis C virus infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. Of all CVDs, heart failure (HF) is a global pandemic affecting at least 26 million people worldwide and is increasing in prevalence causing a heavy burden on patients and their families and on society, through enormous use of health care resources[2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
